Phio Pharmaceuticals Reports Q3 2026 Results and Business Update as It Advances PH-762 Toward Phase 2b Study
The Detroit News
Phio Pharmaceuticals reports its Q3 2026 results, highlighting advancements in its drug development, specifically PH-762, which is set to progress to a Phase 2b study.
The company shares an update on its business, emphasizing its commitment to revolutionizing the pharmaceutical landscape.
The text does not contain any lists or additional elements that require transformation based on the provided guidelines.